FDA Approves Unknown Drug — AZURITY PHARMACEUTICALS INC
On September 25, 2026, Acurity Pharmaceuticals secured an FDA approval for its newly developed generic medication, promising a significant expansion of its market footprint within …
SEC 8-K filings, insider trades, FDA approvals, Federal Reserve statements, and market-moving events — AI-curated, updated every 60 seconds.
On September 25, 2026, Acurity Pharmaceuticals secured an FDA approval for its newly developed generic medication, promising a significant expansion of its market footprint within …
NOVITIUM PHARMA announced today that the FDA has granted approval for its generic application ANDA218687, signaling a successful entry into the market for the referenced substance.…
ADAPTIS announced that the FDA has granted final approval for its ANDA revision to Fluvencanib, a complex Bioequivalence (BE) study essential for securing market entry for its Bupr…
On September 25, 2026, Mirum Pharmaceuticals announced the approval of its new investigational therapy, a strategic expansion that is expected to capture significant market share i…
MEITHEAL has received FDA approval for its generic drug application ANDA213131, driving immediate market opportunities as competitors lose exclusivity rights. This clearance signif…
FDA Approves Merck's Belzutifan With Lenvatinib For Advanced Kidney Cancer With Clear Cell Component
FDA has approved a generic drug under Application #ANDA211255 manufactured by ACTAVIS LABS FL, removing any potential generic competition for the subject product. The approval is e…
FDA has granted approval to NEPHRON for the brand name drug referenced in ANDA215268, a regulatory milestone that solidifies the company's position in the market. Although the spec…
Noviti Pharma has gained regulatory approval for the ANDA220597 drug, a milestone that establishes a new proprietary pathway into the market and positions the company to capitalize…
HIKMA has received approval for the generic version of the undisclosed substance, effective September 18, 2026, positioning the company to capitalize on the upcoming U.S. market la…
Despite lacking a specific brand or generic name in the record, AUROBINDO PHARMA LTD is positioned for incremental revenue following the September 17, 2026, FDA approval of its AND…
DIFGEN PHARMS announced FDA approval on September 15, 2026, for the ANDA application #220657, entering a pathway likely to disrupt market supply and competitive pricing dynamics. I…
Macleods Pharmaceuticals has secured approval from the U.S. Food and Drug Administration for ANDA 210944, a development expected to significantly expand its manufacturing capacity …
Amgen Says FDA Approved Prescribing Information Update Cutting IMDELLTRA Monitoring Time For First Two Doses To 6 To 8 Hours From 22 To 24 Hours
On September 14, 2026, AUROLIFE PHARMA LLC received FDA approval for ANDA 214418, underlining its capacity to expand its generic portfolio and leverage additional market share amid…
Indian generic drugmaker ZYDUS LIFESCIENCES anticipates a new revenue stream following this approval. The new authorization strengthens the company’s portfolio in the market segmen…
Zydus Pharmaceuticals has secured an generic near-term approval on the ANDA219832 trademark application, allowing the company to mark territory within the expanding low-cost drug s…
Baxter Healthcare Corporation has received final FDA approval to manufacture a generic drug designated by ANDA217072, a development anticipated to bolster the company’s revenue str…
RUBICON RESEARCH has received FDA approval for ANDA220884, signaling a significant milestone in its portfolio and positioning the company to capitalize on a substantial market oppo…
Hetero Labs Ltd V announced the FDA approval of ANDA211182 on September 8, 2026, which is expected to broaden market competition and drive price erosion for the generic version of …